The Use of Nutraceuticals in Patients with “Dry” Form of Age-Related Macular Degeneration on the Background of Accelerated Aging

The lutein-containing vitamin-mineral complex Retinorm, developed on the basis of the formula AREDS 2, with an optimal content of vitamins and minerals involved in antioxidant protection, is a potentially promising ophthalmic geroprotector.

Purpose: to evaluate the effectiveness of vitamin-mineral complex “Retinorm” in patients with the dry form of AMD and accelerated pace of aging.

Patients and Methods. The study involved 40 patients with a dry form of AMD (stage 2.3 according to AREDS classification) with an accelerated rate of aging (biological age of patients was measured by the method of Tokar, 1990). Gender distribution: men — 15 (37.5 %), women — 25 (62.5 %). The mean age of patients was 67.3 ± 6.8 years. Patients were divided into 2 groups. Patients of the study group (n = 20) were assigned “Retinorm” 1 capsule 3 times a day for 16 weeks. Patients of the control group (n = 20) were treated with “Lutein Forte” 1 capsule 2 times a day for 16 weeks. Visometry, perimetry, optical coherence tomography of the macular zone, measurement of biological age at the beginning of the study, at 2 and 4 months of the study, the tolerability of treatment in patients with a dry form of age — related macular degeneration on the background of taking dietary supplements-vitamin and mineral complexes with lutein and zeaxanthin.

Results and discussion. As a result of treatment, there were the positive dynamics in terms of visometry and perimetry in the main and control groups. There were no negative dynamics of the indicators of thickness of the retina (in the area of the fovea), and increased macular volume in the main group. In the control group there was a weak tendency to the growth of these indicators. We found a significant positive effect of Retinol on the biological age of patients to 4 months of therapy. It allows to consider the drug as a promising ophthalmoscopy an agent. The results of the study showed the effectiveness of the inclusion of “Retinorm” in patients with the dry form of AMD. The proven geroprotective effect of “Retinorm” with good tolerability of treatment and the absence of side effects from all organ systems with a long term of administration allows us to recommend it for wide use in patients with a dry form of age-related macular degeneration, including patients with an accelerated rate of aging. 

1. Avetisov S.E., Egorov E.A., Moshetova L.K., Neroev V.V., Takhchidi Kh.P. Ophthalmology: national leadership. Moscow: GEOTAR-Media, 2008. 944 p. (In Russ.).

2. Hyman L., Schachat A.P., He Q., Leske M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Archives of Ophthalmology. 2000;118(3):351–358. DOI: 10.1001/archopht.118.3.351

3. Gass J.D. Choroidal neovascular membranes their visualization and treatment. Trans.Am.Acad. Ophthal. Otolaryng. 1973;77:310–320.

4. Bressler N.M., Silva J.C., Bressler S.B. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina. 2005;25:130–142.

5. Yastrebov A. P., Meshchaninov V.N. Aging, lipid peroxidation and biotrust. UGMA. Ekaterinburg, 2005. (Yekaterinburg: Ural Pathfinder): 217 p. (In Russ.).

6. Anisimov V.N. Fundamental gerontology at the turn of the century. Clinical gerontology = Klinicheskaya gerontologiya. 2000;(1):25–32 (In Russ.).

7. Kalous M. The role of mitochondria in aging. Physiol. Res.1996;45(5):351–359.

8. Zhang Y., Saum K.U., Schöttker B. Methylomic survival predictors, frailty, and mortality. Aging (Albany NY). 2018:10;339–357. DOI: 10.18632/aging.101392

9. Lyle B.J., Mares-Perlman J.A., Klein B.E., et al. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Am.J. Epidemiol. 1999;149(39):801–809.

10. Beatty S., Koh H-H. Henson D., Bouston M. Role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000;45:115– 134.

11. Barnett Y.A., King C.M. An investigation of antioxidant status, DNA repair capacity and mutation as a function of age in humans. Mutat. Res. DN Aging: Gen. Instab. and Aging. 1995:338;115–128.

12. Mitnitski A. B. Epigenetic Biomarkers for Biological Age. Epigenet. Aging Longevity. Translat. Epigenet. 2018:4;153–170.

13. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013:309(19):2005–2015. DOI: 10.1001/jama.2013.4997

14. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology. 2001;119(10):1417–1436. DOI: 10.1001/archopht.119.10.1417

15. Moeller S.M., Parekh N., Tinker L., et al. Associations between intermediate age — related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age — related Eye Disease Study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol. 2006;124:1151–1162. DOI: 10.1001/ archopht.124.8.1151